Covid 19

Firstly we’d like to say a big thank you to those of you working on the clinical ‘front lines’ of the epidemic, and to those of you caring for family and friends, especially those dealing with the particular challenges of dementia.

We at CDCIG are doing whatever we can to contribute to Cochrane’s response to COVID-19, both as individuals in our respective fields and as a review group. Detailed information about Cochrane’s response can be found on Cochrane’s COVID-19 webpage. 

Although dementia and cognition may not seem of immediate relevance in a viral pandemic, the indirect effects of COVID are now being seen in dementia care.  For example, COVID can be complicated by severe delirium. People with dementia and their caregivers may be especially vulnerable not only to COVID-19, but also to the effects of social isolation. Movement restrictions may limit visits from family and friends and clinical dementia services are increasingly being delivered remotely.  

We recently updated our review Simulated Presence therapy for dementia and we have a new intervention review in progress on 'Remotely-delivered information, training and support for informal caregivers of people with dementia'. Keeping clinical services going is also a challenge and we have 3 new DTA reviews underway:

 COVID-19 is often associated with delirium, so our delirium reviews may be of interest:

 We’d be very interested to hear from you if there are other dementia-related topics you think would benefit from a systematic review in the context of the COVID-19 pandemic.

Please contact Sue Marcus (Managing Editor), sue.marcus@rdm.ox.ac.uk